ReviewLung cancer management2020
Choosing the best first-line therapy: NSCLC with no actionable oncogenic driver.
Review in Lung cancer management, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Cost-effectiveness models of non-small cell lung cancer: A systematic literature review.Journal of managed care & specialty pharmacy · 2025Pooled it
- Pooled it
- Trastuzumab Deruxtecan inThe New England journal of medicine · 2022Trial
- Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC).AAPS PharmSciTech · 2026Article
- Myeloid-Derived Growth Factor-Regulated Oncogenesis in Lung Adenocarcinoma Is Associated with EGFR Status and Cancer Aggressiveness.Journal of proteome research · 2025Article
- The Impact of Age on the Effectiveness of Immune Checkpoint Inhibitors Therapy in Patients with Metastatic Non-Small-Cell Lung Cancer.Geriatrics (Basel, Switzerland) · 2025Article
- Predicting PD-L1 status in NSCLC patients using deep learning radiomics based on CT images.Scientific reports · 2025Article
- Molecular hydrogen as a potential mediator of the antitumor effect of inulin consumption.Scientific reports · 2025Article
- Real-World Treatment Patterns, Healthcare Resource Utilization, and Healthcare Costs in the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the US.Current oncology (Toronto, Ont.) · 2025Observational
- Gender Matters. Sex-related Differences in Immunotherapy Outcome in Patients with Non-small Cell Lung Cancer.Current cancer drug targets · 2025Article
- Real-World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)-Mutant Metastatic Non-Small Cell Lung Cancer, From a US-Based Clinico-Genomic Database.Cancer medicine · 2024Observational
- A first-in-human phase I study of the PD-1 inhibitor, retifanlimab (INCMGA00012), in patients with advanced solid tumors (POD1UM-101).ESMO open · 2024Article
- Review
- Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.Current oncology (Toronto, Ont.) · 2023Article
- RB1 aberrations predict outcomes of immune checkpoint inhibitor combination therapy in NSCLC.Frontiers in oncology · 2023Article
- [Dual Immunotherapy in Advanced Non-small Cell Lung Cancer: the Progress and Clinical Application].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2022Review
- A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.Medical oncology (Northwood, London, England) · 2022Article
- The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.Frontiers in immunology · 2022Review
- Biomarkers of response to checkpoint inhibitors beyond PD-L1 in lung cancer.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Review
- Correlation between PD-L1 expression andOncotarget · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combination platinum-based therapy has been the standard of care for the treatment of advanced non-small-cell lung cancer (NSCLC). Immunotherapy has emerged and demonstrated to show benefit in the treatment of patients with advanced NSCLC. In this review, we discuss the pivotal trials that led to the US FDA approval of specific immunotherapy regimens in particular patient populations. We discuss the optimal use of immunotherapy as monotherapy based on the KEYNOTE-024, KEYNOTE-042 and IMpower110 trials, chemo-immunotherapy based on KEYNOTE-189, KEYNOTE-407, IMpower150 and IMpower130 trials, and as doublet immunotherapy based on CheckMate-227. We also discuss the role and limitations of PD-L1 expression and tumor mutational burden as predictive biomarkers in response to single-agent immunotherapy and combination chemoimmunotherapy. Furthermore, we discuss emerging resistance markers such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.